Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brodalumab in Axial Spondyloarthritis
NCT02985983Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Mar 2017
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in axial spondyloarthritis (axSpA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) comparing Brodalumab with Placebo (2 arms). Primary endpoint: Assessment of SpondyloArthritis international Society 40 response at 16 weeks. Started Mar 2017; status: completed.
02
Drugs
brodalumab
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NCT02985983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02985983.